• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Phathom

Quote








anonymous said:
I have enjoyed launching Voquenza. The response has been great. It is extremely frustrating having to use Blink. My success has come by bypassing this nightmare SP. The good news is we are getting close to being acquired by a real GI company. Takeda, Abbvie and a couple other GI companies are looking at us. We could get to blockbuster status in a few short years with the vision and support of a larger company with proper MC support. We all just need to hold on until better times arrive.
Click to expand...

I love reading these posts. I am doing well in a C Market Basket. Were not forced to use Blink. I use Blink with the doctors that like it and local retail where they dont. pretty simple. Seems like we have way too many reps like you and thats the reason for the slow start.
 




anonymous said:
I have enjoyed launching Voquenza. The response has been great. It is extremely frustrating having to use Blink. My success has come by bypassing this nightmare SP. The good news is we are getting close to being acquired by a real GI company. Takeda, Abbvie and a couple other GI companies are looking at us. We could get to blockbuster status in a few short years with the vision and support of a larger company with proper MC support. We all just need to hold on until better times arrive.
Click to expand...
Takeda wouldnt be selling all of their shares if they planned to buy us..
 




I can’t wait for NSM. Mainly to guess the age gap of everyone’s LinkedIn profile pic. What’s the over/under on someone has a LinkedIn profile pic 15 years old?
Any takers on half of the sales force using Voquezna?
 




anonymous said:
I can’t wait for NSM. Mainly to guess the age gap of everyone’s LinkedIn profile pic. What’s the over/under on someone has a LinkedIn profile pic 15 years old?
Any takers on half of the sales force using Voquezna?
Click to expand...
NSM? LMAO closest thing we will have is a visual meeting so that Joe can read off a few slides.
 








anonymous said:
Phathom will probably be sold this year, Stringer is hinting at that. The market cap is low and once money gets tight it will be a cheap asset to acquire. It will take lots of cash and patience to get vono to blockbuster status and in 3-5 years there will be 2 or 3 other PCABs on the market. To fight off competition while you are still creating the PCAB market in the US is better done by a large pharma player with deep pockets. Japan shows the potential but Phathom just does not have coffers deep enough to get there alone. My two cents worth.

If you consider s 50% acquisition premium the stock will ball around 15-17 in my opinion, maybe 20 so can make your calculations on the option pool.
Click to expand...
I sure hope so. I believed in our company and bought some stock. I lose more from this crashing company than i make every day. The koolaid tasted so good and i really thought this product was special
 




anonymous said:
I sure hope so. I believed in our company and bought some stock. I lose more from this crashing company than i make every day. The koolaid tasted so good and i really thought this product was special
Click to expand...

The product is great! Sounds like you’re not very good at selling it. I had over 30 prescriptions this week. I bet you’re still at 2.
 












anonymous said:
you’re a moron. Everyone’s territory is different. Bet you have a load of speakers in a major metropolitan area. Damn you are good!
Click to expand...
I have no speakers at all. I don’t need them to be effective. If you’re depending on speakers to be successful then you are in the wrong industry. I feel bad for you.
 




































Top Bottom
Back
Quote